This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

The Norwegian Sonothrombolysis in Acute Stroke Study (NOR-SASS)

This study is currently recruiting participants.
See Contacts and Locations
Verified March 2017 by Haukeland University Hospital
Sponsor:
Collaborator:
University of Bergen
Information provided by (Responsible Party):
Haukeland University Hospital
ClinicalTrials.gov Identifier:
NCT01949961
First received: September 21, 2013
Last updated: March 1, 2017
Last verified: March 2017
September 21, 2013
March 1, 2017
January 2016
December 2019   (Final data collection date for primary outcome measure)
  • Clinical: Functional handicap [ Time Frame: 90 days ]
    Sliding dichotomy/responder analysis: Excellent outcome is defined as modified Rankin Scale (mRS) 0 with baseline National Institutes of Health Stroke Scale (NIHSS), as mRS 0-1 with baseline NIHSS 8-14, as mRS 0-2 with baseline NIHSS ≥15
  • Proof of concept: Early neurological improvement [ Time Frame: 22-36 hours ]
    NIHSS=0 or reduction of ≥4 NIHSS points compared with baseline
Functional handicap [ Time Frame: 90 days ]
modified Rankin Scale score (mRS) 0-1
Complete list of historical versions of study NCT01949961 on ClinicalTrials.gov Archive Site
  • Symptomatic intracerebral hemorrhage [ Time Frame: 24-36 hours ]
    Local or remote parenchymal haemorrhage type 2 on the 22-36 h post-treatment imaging scan, combined with a neurological deterioration of 4 points or more on the NIHSS from baseline or from the lowest NIHSS value between baseline and 24 h, or leading to death (SITS-MOST criteria).
  • Hemorrhagic transformation [ Time Frame: 24-36 hours ]
    Any hemorrhagic changes (infarct or parenchymal hematoma)
  • Short term functional outcome [ Time Frame: 7 days ]
    Sliding dichotomy/responder analysis: Excellent outcome is defined as mRS 0 with baseline NIHSS ≤7, as mRS 0-1 with baseline NIHSS 8-14, as mRS 0-2 with baseline NIHSS ≥15
  • Brain infarct size and location [ Time Frame: 22-36 hours ]
    MRI infarct volume and ASPECTS score
  • Symptomatic intracerebral hemorrhage [ Time Frame: 24-36 hours ]
    Local or remote parenchymal haemorrhage type 2 on the 22-36 h post-treatment imaging scan, combined with a neurological deterioration of 4 points or more on the NIHSS from baseline or from the lowest NIHSS value between baseline and 24 h, or leading to death (SITS-MOST criteria).
  • Hemorrhagic transformation [ Time Frame: 24-36 hours ]
    Any hemorrhagic changes (infarct or parenchymal hematoma)
  • Early clinical outcome [ Time Frame: 2 and 24 hours ]
    1. NIHSS=0 or reduction of ≥4 NIHSS points compared with baseline
    2. Absolute reduction in NIHSS
  • Short term functional outcome [ Time Frame: 7 days ]
    Sliding dichotomy/responder analysis: Excellent outcome is defined as mRS 0 with baseline NIHSS ≤7, as mRS 0-1 with baseline NIHSS 8-14, as mRS 0-2 with baseline NIHSS ≥15
Not Provided
Not Provided
 
The Norwegian Sonothrombolysis in Acute Stroke Study
Randomised Trial of Contrast-enhanced Sonothrombolysis in Acute Ischaemic Stroke

BACKGROUND: Thrombolytic drugs may dissolve blood vessel clots in acute ischemic stroke. The overall benefit of intravenous thrombolysis is substantial, but up to 2/3 of patients with large clots may not achieve re-opening of the vessel and up to 40% of the patients may remain severely disabled or die. Ultrasound accelerates clot break-up (lysis) when combined with thrombolysis (sonothrombolysis) and increases the likelihood of functional independence at 3 months. Adding intravenous ultrasound contrast (gaseous microspheres) further enhances the thrombolytic effect (contrast enhanced sonothrombolysis = CEST). Contrast enhanced ultrasound may also accelerate clot break-up in the absence of thrombolytic drugs (contrast enhanced sonolysis = CES).

HYPOTHESIS: Contrast enhanced ultrasound treatment administered within 4 1/2 hours after symptom onset may be given safely to patients with acute ischemic stroke, both to those receiving intravenous thrombolysis and those not receiving intravenous thrombolysis, and will improve clinical outcome.

AIMS: To compare efficacy and safety of contrast enhanced ultrasound treatment vs. no ultrasound treatment in patients with acute ischemic stroke receiving or not receiving intravenous thrombolysis.

STUDY ENDPOINTS: The primary endpoints are 1) neurological improvement at 24 hours (proof of concept) and 2) excellent clinical outcome at 3 months (effect). Secondary endpoints are bleeding complications (safety), brain damage (infarct size/location) and early clinical improvement (effect).

NOR-SASS aims at testing contrast enhanced sonothrombolysis in all patients with acute ischemic stroke. Patients eligible for thrombolysis (randomized tenecteplase or alteplase) are included in the NOR-SASS A sub-study, patients receiving standard (non-trial) thrombolysis with alteplase are included in the NOR-SASS B sub-study, and patients not eligible for thrombolysis are included in the NOR-SASS C sub-study.

DESIGN: NOR-SASS is a PROBE (prospective randomised, open-label, blinded endpoint) trial, designed to establish the superiority of contrast-enhanced ultrasound treatment given within 4½ hours after stroke onset in consecutively admitted patients with acute ischaemic stroke, as compared with 1) standard iv thrombolysis with tenecteplase (TNK) or alteplase (tPA) in patients eligible for thrombolytic treatment, and 2) no specific treatment in patients not eligible for thrombolytic treatment.

HYPOTHESIS: 1.) In patients eligible for intravenous thrombolysis, contrast enhanced sonothrombolysis (CEST) has superior effect as compared with standard intravenous thrombolysis and may be given safely. 2.) In patients not eligible for thrombolysis, contrast enhanced sonolysis (CES) has superior effect as compared with no specific treatment and may be given safely.

RANDOMISATION: In NOR-SASS-A (two step randomisation), 1st randomisation is 1:1 to either tenecteplase (TNK) or alteplase (tPA); 2nd randomisation is 1:1 to either CEST or no CEST. In NOR-SASS-B, randomisation is 1:1 to either CEST or no CEST. In NOR-SASS-C, randomisation is 1:1 to either CES or no CES.

Interventional
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary Purpose: Treatment
Ischemic Stroke
  • Other: Ultrasound
    SonoVue solution 10 ml (2 vials / 80 µl microbubbles) is given as an infusion of 0,3 ml/min for ~30 minutes, using a Bracco infusion pump.
  • Other: Sham ultrasound
    Mounting the ultrasound headframe but connecting this to a non-operative channel
  • Active Comparator: Ultrasound
    Patients eligible (NOR-SASS A/B) and ineligible (NOR-SASS C) for intravenous thrombolysis all receive intravenous ultrasound contrast (microbubbles). The groups are separately randomised to 2 megahertz (MHz) transcranial ultrasound treatment for one hour.
    Intervention: Other: Ultrasound
  • Placebo Comparator: Sham ultrasound
    Patients eligible (NOR-SASS A/B) and ineligible (NOR-SASS C) for intravenous thrombolysis all receive intravenous ultrasound contrast (microbubbles). The two groups are separately randomised to sham ultrasound treatment for one hour.
    Intervention: Other: Sham ultrasound

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
180
December 2019
December 2019   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Ischemic stroke in the anterior circulation
  • Treatment within 4.5 hours after stroke onset
  • Informed consent

Exclusion Criteria:

  • Patients with premorbid modified Rankin Scale (mRS) score ≥3;
  • Patients for whom a complete NIH Stroke Score cannot be obtained;
  • Hemiplegic migraine with no arterial occlusion on baseline CT;
  • Seizure at stroke onset and no visible occlusion on baseline CT;
  • Intracranial haemorrhage on baseline CT;
  • Clinical subarachnoid haemorrhage even if baseline CT is normal;
  • Large areas of hypodense ischaemic changes on baseline CT;
  • Patients with primary endovascular treatment;
  • Female, pregnant or breast feeding; pericarditis; sepsis; any other serious medical illness likely to interact with treatment; confounding pre-existent neurological or psychiatric disease; unlikely to complete follow-up; any investigational drug <14 days;
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact: Lars Thomassen, MD PhD Prof. +47 55 97 50 00 ltho@haukeland.no
Contact: Christopher E Kvistad, MD +47 55 97 50 00 echr@helse-bergen.no
Norway
 
 
NCT01949961
REK 2011/2448
2012-000323-41 ( EudraCT Number )
Yes
Not Provided
Not Provided
Haukeland University Hospital
Haukeland University Hospital
University of Bergen
Study Director: Lars Thomassen, MD PhD Prof. Dept. Neurology, Haukeland University Hospital, Bergen, Norway
Study Chair: Christopher E Kvistad, MD Dept. Neurology, Haukeland University Hospital, Bergen, Norway
Principal Investigator: Aliona Nacu, MD Dept. Neurology, Haukeland University Hospital, Bergen, Norway
Haukeland University Hospital
March 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP